• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Cellectar Biosciences Inc.

    11/14/24 4:47:59 PM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLRB alert in real time by email
    SC 13G/A 1 tm2428381d5_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

    Cellectar Biosciences, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.00001 per share
    (Title of Class of Securities)
     
    15117F500
    (CUSIP Number)
     
    September 30, 2024
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

     

    ¨ Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 15117F500

     

    1 Names of reporting persons
    ADAR1 Capital Management, LLC
    2 Check the appropriate box if a member of a group (see instructions)
    (a) ¨
    (b) x
    3 SEC use only
     
    4 Citizenship or place of organization
    Texas
    Number of
    shares
    beneficially
    owned by each
    reporting
    person with:
    5 Sole voting power
    0
    6 Shared voting power
    3,684,708(1)
    7 Sole dispositive power
    0
    8 Shared dispositive power
    3,684,708(1)
    9 Aggregate amount beneficially owned by each reporting person
    3,684,708
    10 Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
    ¨
    11 Percent of class represented by amount in Row (9)
    8.51%(2) 
    12 Type of reporting person (see instructions)
    OO
           

    (1) Includes (i) 929,096 shares of common stock, par value $0.00001 per share (“Common Stock”) held by ADAR1 Partners, LP, (ii) 39,553 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 2,716,062 shares of Common Stock underlying milestone warrants held by ADAR1 Partners, LP as of November 5, 2024. As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC., ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC.
    (2) Based on 40,566,534 shares of Common Stock of Cellectar Biosciences, Inc. (the “Issuer”) outstanding as of October 25, 2024 reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the SEC on October 29, 2024.

     

    2

     

     

    CUSIP No. 15117F500

     

    1 Names of reporting persons
    ADAR1 Capital Management GP, LLC
    2 Check the appropriate box if a member of a group (see instructions)
    (a) ¨
    (b) x
    3 SEC use only
     
    4 Citizenship or place of organization
    Texas
    Number of
    shares
    beneficially
    owned by each
    reporting
    person with:
    5 Sole voting power
    0
    6 Shared voting power
    3,645,155(1)
    7 Sole dispositive power
    0
    8 Shared dispositive power
    3,645,155(1)
    9 Aggregate amount beneficially owned by each reporting person
    3,645,155
    10 Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
    ¨
    11 Percent of class represented by amount in Row (9)
    8.42%(2) 
    12 Type of reporting person (see instructions)
    OO
           

    (1) Includes (i) 929,093 shares of Common Stock directly held by ADAR1 Partners, LP and (ii) 2,716,062 shares of Common Stock underlying milestone warrants held by ADAR1 Partners, LP as of November 5, 2024. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP.
    (2) Based on 40,566,534 shares of Common Stock of the Issuer outstanding as of October 25, 2024 reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the SEC on October 29, 2024.

     

    3

     

     

    CUSIP No. 15117F500

     

    1 Names of reporting persons
    Daniel Schneeberger
    2 Check the appropriate box if a member of a group (see instructions)
    (a) ¨
    (b) x
    3 SEC use only
     
    4 Citizenship or place of organization
    Switzerland

    Number of
    shares
    beneficially
    owned by each
    reporting
    person with:

     

    5 Sole voting power
    0
    6 Shared voting power
    3,684,708(1)
    7 Sole dispositive power
    0
    8 Shared dispositive power
    3,684,708(1)
    9 Aggregate amount beneficially owned by each reporting person
    3,684,708
    10 Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
    ¨
    11 Percent of class represented by amount in Row (9)
    8.51%(2) 
    12 Type of reporting person (see instructions)
    IN
           

    (1) Includes (i) 929,093 shares of Common Stock held by ADAR1 Partners, LP, (ii) 39,553 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 2,716,062 shares of Common Stock underlying milestone warrants held by ADAR1 Partners, LP as of November 5, 2024. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC.
    (2) Based on 40,566,534 shares of Common Stock of the Issuer outstanding as of October 25, 2024 reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the SEC on October 29, 2024.

     

    4

     

     

    Item 1(a) Name of issuer:

     

    Cellectar Biosciences, Inc.

     

    Item 1(b) Address of issuer’s principal executive offices:

     

    100 Campus Drive, Florham Park, New Jersey 07932

     

    Item 2(a) Name of person filing:

     

    This Schedule is being filed on behalf of each of the following persons (each, a “Reporting Person” and collectively, the “Reporting Persons”):

     

      (i) ADAR1 Capital Management, LLC (“ADAR1 Capital Management”);
      (ii) ADAR1 Capital Management GP, LLC (“ADAR1 General Partner”); and
      (iii) Daniel Schneeberger (“Mr. Schneeberger”).

     

    Item 2(b) Address or principal business office or, if none, residence:

     

    The address of the principal business office of each of the Reporting Persons is 3503 Wild Cherry Drive, Building 9, Austin, Texas 78738.

     

    Item 2(c) Citizenship:

     

      (i) ADAR1 Capital Management is a Texas limited liability company;
      (ii) ADAR1 General Partner is a Texas limited liability company; and
      (iii) Mr. Schneeberger is a citizen of Switzerland.

     

    Item 2(d) Title of Class of Securities:

     

    Common Stock, par value $0.00001 per share

     

    Item 2(e) CUSIP No.:

     

    15117F500

     

    5

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

     

      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);

     

      (c) ¨ Insurance company defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);

     

      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); 

     

      (e) x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); 

     

      (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); 

     

      (g) x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); 

     

      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3); 

     

      (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J); 

     

      (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). 

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ______________.

     

    Item 4. Ownership

     

    ADAR1 Capital Management, LLC  

     

    Amount beneficially owned:   3,684,708 
    Percent of class:   8.51%
    Number of shares as to which the Reporting Person has:     
    Sole power to vote or direct the vote:   0 
    Shared power to vote or direct the vote:   3,684.708 
    Sole power to dispose or direct the disposition of:   0 
    Shared power to dispose or direct the disposition of:   3,684.708 

     

    ADAR1 Capital Management GP, LLC  

     

    Amount beneficially owned:   3,645,155 
    Percent of class:   8.42%
    Number of shares as to which the Reporting Person has:     
    Sole power to vote or direct the vote:   0 
    Shared power to vote or direct the vote:   3,645,155 
    Sole power to dispose or direct the disposition of:   0 
    Shared power to dispose or direct the disposition of:   3,645,155 

     

    Daniel Schneeberger  

     

    Amount beneficially owned:   3,684.708 
    Percent of class:   8.51%
    Number of shares as to which the Reporting Person has:     
    Sole power to vote or direct the vote:   0 
    Shared power to vote or direct the vote:   3,684.708 
    Sole power to dispose or direct the disposition of:   0 
    Shared power to dispose or direct the disposition of:   3,684.708 

     

    6

     

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    7

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 14, 2024

     

      ADAR1 CAPITAL MANAGEMENT, LLC
       
      /s/ Daniel Schneeberger
      Daniel Schneeberger
      Manager
       
      ADAR1 CAPITAL MANAGEMENT GP, LLC
       
      /s/ Daniel Schneeberger
      Daniel Schneeberger
      Manager
       
      /s/ Daniel Schneeberger
      Daniel Schneeberger, in his individual capacity

     

    8

     

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to shares of common stock, par value $0.00001 per share of Cellectar Biosciences, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings.

     

    In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement as of November 14, 2024.

     

      ADAR1 CAPITAL MANAGEMENT, LLC
       
      /s/ Daniel Schneeberger
      Daniel Schneeberger
      Manager
       
      ADAR1 CAPITAL MANAGEMENT GP, LLC
       
      /s/ Daniel Schneeberger
      Daniel Schneeberger
      Manager
       
      /s/ Daniel Schneeberger
      Daniel Schneeberger, in his individual capacity

     

    9

     

    Get the next $CLRB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLRB

    DatePrice TargetRatingAnalyst
    12/5/2024$13.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $CLRB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ladenburg Thalmann resumed coverage on Cellectar Biosciences with a new price target

      Ladenburg Thalmann resumed coverage of Cellectar Biosciences with a rating of Buy and set a new price target of $13.00

      12/5/24 8:32:15 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLRB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Longcor Jarrod bought $8,400 worth of shares (30,000 units at $0.28), increasing direct ownership by 56% to 83,141 units (SEC Form 4)

      4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

      3/12/25 9:44:18 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLRB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025

      FLORHAM PARK, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the Company will report financial results for the first quarter ended March 31, 2025, and provide a corporate update on May 13, 2025, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Tuesday, May 13, 2025Time:8:30 am Eastern TimeToll Free:1-800-717-1738Conference ID:53983Webcast:Click HERE A replay of the corporate presentation will be available on the Events section of the Company's Investor Relations website.

      5/7/25 8:05:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Announces Plan to Explore Strategic Alternatives

      FLORHAM PARK, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the company will explore a full range of strategic alternatives to advance its promising platform and radiopharmaceutical drug development pipeline to maximize stockholder value. Strategic alternatives under consideration may include, but are not limited to mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions. The company's board of directors has approved the engagement of Op

      4/30/25 8:05:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update

      Achieves alignment with U.S. Food and Drug Administration (FDA) on regulatory path for potential accelerated approval of iopofosine I 131 as a treatment for Waldenström macroglobulinemia (WM) Evaluating timing for Phase 1 solid tumor studies; Auger-emitting radioconjugate prepared for Phase 1b; plans to submit an IND for alpha-emitting radioconjugate; Company to host webcast and conference call at 8:30 AM ET today FLORHAM PARK, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced fin

      3/13/25 7:05:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLRB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Longcor Jarrod bought $8,400 worth of shares (30,000 units at $0.28), increasing direct ownership by 56% to 83,141 units (SEC Form 4)

      4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

      3/12/25 9:44:18 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Swirsky Douglas J

      4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

      2/18/25 4:07:24 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Neis John

      4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

      2/18/25 4:06:31 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLRB
    Financials

    Live finance-specific insights

    See more
    • Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025

      FLORHAM PARK, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the Company will report financial results for the first quarter ended March 31, 2025, and provide a corporate update on May 13, 2025, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Tuesday, May 13, 2025Time:8:30 am Eastern TimeToll Free:1-800-717-1738Conference ID:53983Webcast:Click HERE A replay of the corporate presentation will be available on the Events section of the Company's Investor Relations website.

      5/7/25 8:05:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update

      Achieves alignment with U.S. Food and Drug Administration (FDA) on regulatory path for potential accelerated approval of iopofosine I 131 as a treatment for Waldenström macroglobulinemia (WM) Evaluating timing for Phase 1 solid tumor studies; Auger-emitting radioconjugate prepared for Phase 1b; plans to submit an IND for alpha-emitting radioconjugate; Company to host webcast and conference call at 8:30 AM ET today FLORHAM PARK, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced fin

      3/13/25 7:05:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025

      FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the company will report financial results for the full year ended December 31, 2024, and provide a corporate update on March 13, 2025, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Thursday, March 13, 2025Time:8:30 am Eastern TimeToll Free:1-800-717-1738Conference ID:Webcast:           25759Click HERE A replay of the call will be available on the Events section of the company's Investor Relations website.

      3/5/25 8:05:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLRB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cellectar Biosciences Inc.

      SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)

      11/14/24 4:47:59 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cellectar Biosciences Inc.

      SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)

      11/14/24 1:26:20 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cellectar Biosciences Inc.

      SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)

      8/14/24 7:15:55 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLRB
    Leadership Updates

    Live Leadership Updates

    See more
    • Cellectar Biosciences Expands Commercialization Leadership Team Ahead of Pivotal Data for Iopofosine I-131 in Waldenstrom's Macroglobulinemia

      William Yoon Appointed Vice President, Medical Affairs Aaditya Nanduri Appointed Vice President, Business Strategy and Analytics FLORHAM PARK, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of targeted drugs for the treatment of cancer, is pleased to announce the appointment of William Yoon, PharmD, MBA/HCM as vice president, medical affairs and Aaditya Nanduri, MS, as vice president, business strategy and analytics ahead of the expected readout of top-line pivotal data for iopofosine I 131 in Waldenstrom's macroglobulinemia (WM) in Q4 2023. "

      10/17/23 8:00:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MaxCyte Appoints Douglas Swirsky as Chief Financial Officer

      ROCKVILLE, Md., March 27, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced Douglas J. Swirsky has been appointed as the Company's Chief Financial Officer, effective immediately. Mr. Swirsky is a seasoned financial leader with over two decades of experience in the healthcare sector, including as a public company executive at Nasdaq-listed organizations. "We are excited to welcome Douglas to MaxCyte where he brings exceptio

      3/27/23 4:05:00 PM ET
      $CLRB
      $MXCT
      $REXN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Major Pharmaceuticals
    • Cellectar Biosciences Announces Shane Lea as Chief Commercial Officer

      FLORHAM PARK, N.J., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the appointment of Shane Lea as its chief commercial officer, effective November 21, 2022. Mr. Lea brings to Cellectar Biosciences comprehensive commercial leadership experience in hematology and oncology. In his most recent role as senior vice president hematology at TG Therapeutics, he oversaw the sales, marketing and analytics teams for the hematology franchise. Prior to TG Therapeutics, Mr. Lea served as vice president, hematology

      11/30/22 8:30:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLRB
    SEC Filings

    See more
    • Cellectar Biosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Cellectar Biosciences, Inc. (0001279704) (Filer)

      5/1/25 6:04:27 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Cellectar Biosciences Inc.

      DEFA14A - Cellectar Biosciences, Inc. (0001279704) (Filer)

      4/28/25 4:36:07 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Cellectar Biosciences Inc.

      DEF 14A - Cellectar Biosciences, Inc. (0001279704) (Filer)

      4/28/25 4:31:16 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care